Articles tagged with Cancer Vaccines
Researchers at the University of Pennsylvania developed lipid nanoparticles that modify immune metabolism to strengthen mRNA vaccines and reduce common side effects. The new lipid boosts the metabolism of immune cells, providing energy for the body's defenses while dialing down inflammatory signals.
Researchers have engineered Listeria bacteria to stimulate the body's innate immune system and eliminate cancer cells. The therapy, which boosts gamma delta T cells, shows promise in treating children with leukemia and preventing graft-versus-host disease.
A new HPV cancer vaccine developed by Northwestern University scientists has shown promising results in a preclinical model. The vaccine's carefully organized structure dramatically enhances the immune system's ability to attack tumors, shrinking them and extending animal survival.
Researchers at Mount Sinai detail how decades of cancer vaccine research have converged into more precise and effective immunotherapies. Decades-long clinical trials show personalized neoantigen vaccines are safe and capable of generating robust immune responses across various cancers.
The University of Texas MD Anderson Cancer Center has made significant advancements in cancer care through its collaborative efforts between clinicians and scientists. These breakthroughs include an immune-targeting vaccine that shows promise in intercepting cancer in patients with Lynch Syndrome, a novel immunotherapy that demonstrate...
The study found that the investigational vaccine produced an immune response in 74% of participants and was safe and well-tolerated. A Phase 2 study is planned to evaluate the vaccine's efficacy, offering new hope for triple-negative breast cancer treatment.
The ESMO Immuno-Oncology Congress 2025 will discuss key developments in immuno-oncology, including combined approaches, AI in cancer therapy, and innovative strategies across various cancers. The congress aims to advance the field of immunotherapy and improve patient outcomes.
A new study has developed a calcium-activated delivery system that enables more precise cancer treatment, reducing side effects and improving outcomes. The system uses a 'calcium switch' to target tumor cells, releasing a lethal payload deep within, while sparing healthy tissue.
Researchers at Chiba University have developed a nasal therapeutic vaccine targeting E7 oncoprotein, which is produced by high-risk strains of HPV associated with cervical cancer. The vaccine triggers an immune response in the cervical mucosa, providing local protection against pathogens and foreign particles.
The review highlights how T cells specifically recognize and eliminate malignant cells through antigen recognition mechanisms. It also explores how tumors evade immune surveillance through various mechanisms and discusses potential therapeutic strategies, including combination therapies to improve response rates for cancer patients.
Researchers have discovered an experimental mRNA vaccine that can boost tumor-fighting effects of immunotherapy, sparking a new approach to battling many types of treatment-resistant tumors. The study found that pairing the test vaccine with common anticancer drugs triggered a strong antitumor response.
The inaugural ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025 will convene a diverse group of stakeholders to foster collaboration and accelerate the development of innovative cancer therapies. The congress aims to become a catalyst for global collaboration and innovation in oncology.
Researchers discuss advancements in pancreatic cancer detection using biomarkers, imaging techniques, and molecular diagnostics. Novel therapies targeting the tumor microenvironment and immune evasion mechanisms are explored to improve survival outcomes.
The project aims to enhance CTC detection sensitivity and specificity for clinical needs in cancer early screening, diagnosis and treatment. The team will develop an integrated system covering CTC counting, classification and downstream detection of CTC proteins and genes.
Researchers at Tufts University have developed a cancer vaccine that amplifies the visibility of tumor antigens to the immune system, leading to potent responses and lasting immunological memory. The vaccine works against multiple solid tumors in animal models, including melanoma, triple-negative breast cancer, and ovarian cancer.
A phase 1 trial of a personalized cancer vaccine for patients with stage III or IV clear cell renal cell carcinoma showed a positive response in all nine patients, with no higher-grade side effects reported. The vaccine generated a successful anti-cancer immune response and kept patients cancer-free at the time of data cut-off.
Researchers at Terasaki Institute develop lipopeptide hydrogels to deliver peptide-based cancer vaccines, demonstrating sustained release and enhanced immune cell uptake. The system shows promise in overcoming limitations of traditional peptide-based vaccines.
Cancer vaccines hold transformative potential, leveraging neoantigens to activate the immune system against tumors. UK researchers are positioning themselves for a strategic shift in cancer vaccine trials, recognizing opportunities for improvement.
Researchers have engineered probiotic bacteria to educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines. The bacterial vaccine proved more efficacious than peptide-based therapeutic cancer vaccines in studies using mouse models of advanced colorectal and melanoma cancers.
A cancer vaccine demonstrated its effectiveness when administered at an early stage, preventing tumor progression and achieving long-term protection. The study's findings support further investigation into personalized vaccines for cancer treatment.
Researchers from Wyss Institute and Harvard University developed a biomaterial vaccine that enhances and sustains lymph node expansion, leading to more effective anti-tumor responses. The vaccine formulation, based on microscale mesoporous silica rods, reprograms antigen-presenting cells to orchestrate complex immune responses.
A new mRNA cancer vaccine has been shown to trigger a vigorous immune response in both human patients and pet dogs with glioblastoma, the most aggressive form of brain cancer. The breakthrough treatment, which uses a personalized approach and novel delivery mechanism, demonstrates promising results in early clinical trials.
Researchers at Tokyo Medical and Dental University have developed a novel method for coating engineered messenger RNA molecules with polyethylene glycol (PEG), allowing selective delivery to the spleen. This breakthrough enables fine-tuned control over mRNA therapy, facilitating effective treatment of diseases previously considered inc...
Researchers found that an individualized neoantigen-specific mRNA vaccine, autogene cevumeran, can induce a robust immune response in patients with resectable pancreatic cancer. After a median follow-up of three years, the treatment was associated with a significantly longer median recurrence-free survival compared to those who did not...
A second-generation melanoma vaccine has shown improved survival rates for male patients compared to female patients, particularly those who are younger and have earlier-stage cancer. The vaccine targets helper T cells to recognize melanoma proteins, leading to boosted patient survival and reduced cancer reoccurrences.
A new DNA origami platform, DoriVac, enables precise spacing of adjuvant molecules and a variety of antigens to enhance anti-tumor responses. The vaccine demonstrated enhanced efficacy in controlling tumor growth and prolonging survival in mice, synergizing with immune checkpoint inhibitors.
Researchers at the University of Toronto have discovered a novel ionizable lipid nanoparticle that enables efficient muscle-focused mRNA delivery while minimizing off-target effects. The study demonstrates potent cellular immune responses and potential as a viable candidate for cancer vaccine development.
Tedopi, a T-cell epitope-based cancer vaccine, has demonstrated improved overall survival and a better safety profile compared to chemotherapy in HLA-A2 positive patients with advanced or metastatic NSCLC who have progressed after immune checkpoint inhibitors. The Phase 3 trial showed a significant reduction in the risk of death by 41%.
A new mRNA derivative, comb-structured RNA, has been developed to enhance anti-cancer activities by activating immune cells and demonstrating high tumor effects in mice models. The study shows the potential of this novel cancer mRNA vaccine as a safe and effective treatment.
A personalized mRNA-based cancer vaccine, mRNA-4157/V940, improves recurrence-free survival in patients with high-risk melanoma when combined with pembrolizumab. The clinical benefit is observed regardless of tumor mutational burden status.
Researchers developed a new way to increase vaccine potency by changing the structural location of antigens and adjuvants. This approach, called 'rational vaccinology,' allows for precise dosing and tailored presentation of vaccine components, leading to improved immune response and cancer cell targeting.
Researchers have developed a polymeric carrier for mRNA vaccines that reduces inflammation and maintains efficiency, potentially offering better cancer treatment options. The new carrier, tested in preclinical studies, shows promise for low-side-effect cancer therapy.
Researchers found that IV administration of the experimental cancer vaccine, SNAPvax, boosted cytotoxic T cells capable of infiltrating tumor cells and engaged the innate immune system. This approach overcomes tumor-induced immunosuppressive activity, enabling enhanced T-cell immunity.
Researchers at Tufts University have developed a targeted cancer vaccine that delivers mRNA directly to the lymphatic system, resulting in potent immune responses and complete remission in mice with metastatic melanoma. The vaccine's effectiveness was demonstrated by a 40% rate of complete response and excellent immune memory.
Scientists developed a pipeline for identifying and prioritising potential tumour antigens for fast generation of cancer vaccines. The 'plug-and-play' vaccine technology enables rapid, affordable, and feasible approaches to deliver targeted peptides to patients, potentially leading to quicker and easier personalized therapy.
Researchers at Karolinska Institutet have found a way to stabilize the cancer-suppressing protein p53 by adding a spider silk protein, creating a more potent variant. This discovery has potential as an approach for cancer therapy.
MIT researchers have found that vaccinating against certain cancer proteins can boost the overall T cell response and help to shrink tumors in mice. The study identifies specific neoantigens that, when targeted with a vaccine, can reawaken dormant T cell populations and lead to tumor regression.
A new cancer vaccine strategy showed promise in a proof-of-concept study, reducing tumor burden and improving overall survival in an animal model of Lynch syndrome. The vaccine targets specific neoantigens produced by cancer cells, stimulating a robust immune response.
A personalized cancer vaccine developed using a computational platform raised no safety concerns and showed potential benefit in patients with high-risk cancer recurrences. The vaccine was well-tolerated, with minor injection-site reactions, and demonstrated early potential benefits after administration.
Researchers at Thomas Jefferson University have developed a cancer vaccine that shows promise in treating gastric, pancreatic, esophageal, and colon cancers. The new vaccine, Ad5.F35, is more effective than the original version due to its ability to evade the immune system's natural defenses.
The new vaccine targets key tumour cells, maximising effectiveness while minimising side effects. It can be produced as an 'off the shelf' clinical grade formulation, addressing financial and logistical issues.
Researchers at EPFL have created a prototype vaccine that can travel to the desired location and activate immune cells, overcoming two major obstacles in therapeutic cancer vaccines. The Polycondensate Neoepitope (PNE) combines a patented technique with an algorithm for predicting mutated tumor antigens.
Researchers at Duke University Medical Center have developed a poliovirus-based therapy that stimulates a natural immune attack on cancer cells in animal studies. The modified virus, called PVSRIPO, induces an immune response against mutated cancer cells found in diffuse midline glioma tumors, which are universally deadly in children.
Researchers at Arizona State University have discovered a common source of tumor mutations that could lead to the development of universal cancer vaccines. They found that errors in RNA transcription and splicing in tumors can produce unique protein fragments, or peptides, that can be recognized by the immune system.
Researchers developed a cancer vaccine platform that can enhance oncolytic virus efficacy, activating human immune response against cancer cells. By using patient's own peptides, the treatment targets tumour cells, increasing T cell activity and improving therapy.
Researchers developed a new cancer vaccine that boosts the immune system's ability to fight cancers, suggesting increased chances of recovery in cases where drug therapy alone is not working. The vaccine, called Diprovocim, was shown to produce a complete response in treating melanoma and preventing recurrence.
A new personalized vaccine has shown promise in boosting immune responses and increasing survival rates in patients with advanced ovarian cancer. The vaccine combines different immunotherapies to better tackle the disease, which is often diagnosed at later stages and lacks curative treatment options.
Research published in Genome Medicine found that a broad cancer vaccine targeting multiple neo-antigens could only be effective for less than 0.3% of the population, based on analysis of over 60,000 unique tumors.
A new minimally invasive vaccine combines cancer cells with immune-enhancing factors, evoking an immune response in a simpler and more economical way. The approach has shown promising results in experimental animal models, shrinking tumors and protecting animals from tumor growth.
Therapeutic anti-cancer vaccines have been associated with a statistically significant increase in patient survival, but rarely have a noticeable effect on tumor growth. The study suggests that overall survival, rather than progression-free survival, should be the gold standard for evaluating cancer vaccine efficacy.
A recent Special Focus in Human Vaccines & Immunotherapeutics discusses the mistakes of past cancer vaccine programs and provides critical insights into the future of cancer vaccines. The study emphasizes the importance of antigen discovery and personalized approaches to overcome the challenges of tumor heterogeneity.
Therapeutic cancer vaccines are being evaluated in clinical trials with immune checkpoint inhibitors and small-molecule targeted therapies to overcome immunosuppressive entities. Patients with fewer chemotherapeutic regimens respond better to vaccines, indicating a shift towards combination therapies.
Researchers report growing success in combining therapeutic cancer vaccines with conventional chemotherapy, stimulating the immune system to destroy cancer cells. The first FDA-approved cancer vaccine is for metastatic prostate cancer, and several other strategies are being tested for various types of cancer.
Researchers recommend a national strategy for therapeutic cancer vaccines, focusing on cancers with poor treatment options. Vaccines targeting such cancers may offer better survival rates and fewer side effects than current treatments.
Researchers found that inactivating the NLRP3 protein can increase the effectiveness of therapeutic cancer vaccines. This discovery may lead to more effective cancer treatments and is the first to link immature myeloid cells, NLRP3, and vaccine response.
The Bioproduction Facility at Cornell University has produced the first batch of NY-ESO-1 recombinant protein, a cancer vaccine that will be used in clinical trials for patients with ovarian or melanoma. The goal is to maximize the body's immune response to the protein.
A vaccine booster has been shown to induce a persistent immune response against lung cancer, reducing the risk of recurrence. The study found that patients who received regular recall injections experienced improved immunological memory, which can be strengthened with additional vaccinations.
A new vaccine has been developed using a pathogen-mimicking approach, combining CpG 7909 adjuvant and synthetic peptide from melanoma antigen Melan-A/MART-1. The vaccine induced strong T cell responses in all eight patients, with one order of magnitude higher than previous studies.
Cancer researchers have developed a new method to delay dendritic cell activation, extending the time when immune cells can detect and attack cancer. By using a drug that links molecules, the approach prolongs the activity of dendritic cells, which are key to cancer vaccines.
Researchers found that a cancer vaccine can stimulate the production of CTLs against specific antigens and also reactivate spontaneously produced CTL populations against multiple cancer antigens in about 10% of patients with metastatic melanoma. This non-specific process could potentially eliminate bulk of tumor cells.